Einzeltreffer — DigiBib

Phenotypic diversity in urinary metabolomes of different geographical populations has been recognized recently. In this study, urinary metabolic signatures from Western (United Kingdom) and South-East Asian (Thai) cholangiocarcinoma patients were characterized to understand spectral variability due to host carcinogenic processes and/or exogenous differences (nutritional, environmental and pharmaceutical). Urinary liquid chromatography mass spectroscopy (LC-MS) spectral profiles from Thai (healthy = 20 and cholangiocarcinoma = 14) and UK cohorts (healthy = 22 and cholangiocarcinoma = 10) were obtained and modelled using chemometric data analysis. Healthy metabolome disparities between the two distinct populations were primarily related to differences in dietary practices and body composition. Metabolites excreted due to drug treatment were dominant in urine specimens from cholangiocarcinoma patients, particularly in Western individuals. Urine from participants with sporadic (UK) cholangiocarcinoma contained greater levels of a nucleotide metabolite (uridine/pseudouridine). Higher relative concentrations of 7-methylguanine were observed in urine specimens from Thai cholangiocarcinoma patients. The urinary excretion of hippurate and methyladenine (gut microbial-host co-metabolites) showed a similar pattern of lower levels in patients with malignant biliary tumours from both countries. Intrinsic (body weight and body composition) and extrinsic (xenobiotic metabolism) factors were the main causes of disparities between the two populations. Regardless of the underlying aetiology, biological perturbations associated with cholangiocarcinoma urine metabolome signatures appeared to be influenced by gut microbial community metabolism. Dysregulation in nucleotide metabolism was associated with sporadic cholangiocarcinoma, possibly indicating differences in mitochondrial energy production pathways between cholangiocarcinoma tumour subtypes. Mapping population-specific metabolic disparities may aid in interpretation of disease processes and identification of candidate biomarkers.

Titel:	Mapping of population disparities in the cholangiocarcinoma urinary metabolome.
Autor/in / Beteiligte Person:	Alsaleh, M ; Leftley, Z ; O'Connor, T ; Hughes, T ; Barbera, TA ; Koomson, LK ; Zabron, A ; Reeves, H ; Cramp, M ; Ryder, SD ; Greer, S ; Prince, M ; Sithithaworn, P ; Khuntikeo, N ; Loilome, W ; Yongvanit, P ; Cox, IJ ; Williams, R ; Wadsworth, CA ; Holmes, E ; Nash, K ; Andrews, R ; Taylor-Robinson, SD
Link:	Full Text Finder (Volltext)
Zeitschrift:	Scientific reports, Jg. 11 (2021-10-28), Heft 1, S. 21286
Veröffentlichung:	London : Nature Publishing Group, copyright 2011-, 2021
Medientyp:	academicJournal
ISSN:	2045-2322 (electronic)
DOI:	10.1038/s41598-021-00530-0
Schlagwort:	Adult Aged Aged, 80 and over Chromatography, Liquid Female Humans Male Mass Spectrometry Middle Aged Population Surveillance Thailand epidemiology United Kingdom epidemiology Biological Variation, Population Biomarkers urine Cholangiocarcinoma epidemiology Cholangiocarcinoma urine Metabolome Metabolomics
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Sci Rep] 2021 Oct 28; Vol. 11 (1), pp. 21286. <i>Date of Electronic Publication: </i>2021 Oct 28. MeSH Terms: Biological Variation, Population* ; Metabolome* ; Metabolomics* ; Biomarkers / urine ; Cholangiocarcinoma / epidemiology ; Cholangiocarcinoma / *urine ; Adult ; Aged ; Aged, 80 and over ; Chromatography, Liquid ; Female ; Humans ; Male ; Mass Spectrometry ; Middle Aged ; Population Surveillance ; Thailand / epidemiology ; United Kingdom / epidemiology References: Nature. 2008 May 15;453(7193):396-400. (PMID: 18425110) ; World J Gastroenterol. 2008 Feb 7;14(5):666-74. (PMID: 18205254) ; J Gastroenterol Hepatol. 2002 Oct;17(10):1049-55. (PMID: 12201863) ; J Obes. 2014;2014:410259. (PMID: 24757561) ; Cell. 2016 Jul 28;166(3):555-566. (PMID: 27471965) ; Acta Pathol Jpn. 1992 Oct;42(10):734-9. (PMID: 1334615) ; Diabetes Care. 2016 May;39(5):833-46. (PMID: 27208380) ; BMC Cancer. 2015 Jun 09;15:459. (PMID: 26054405) ; J Proteome Res. 2013 Apr 5;12(4):1527-46. (PMID: 23342949) ; Asian Pac J Cancer Prev. 2009;10(5):961-2. (PMID: 20162855) ; J Nutr. 1993 May;123(5):909-14. (PMID: 8487102) ; Cell Metab. 2012 May 2;15(5):606-14. (PMID: 22560213) ; J Hepatol. 2011 Oct;55(4):896-905. (PMID: 21334394) ; J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Apr 13;834(1-2):155-62. (PMID: 16554191) ; J Anim Sci Biotechnol. 2017 Jan 23;8:10. (PMID: 28127425) ; Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. (PMID: 27095655) ; J Chromatogr B Biomed Sci Appl. 2001 Feb 10;751(1):87-92. (PMID: 11232859) ; J Nutr. 2015 Apr;145(4):766-74. (PMID: 25833779) ; Cancer Metab. 2015 Jan 25;3(1):1. (PMID: 25621173) ; Environ Toxicol. 2015 Jul 8;30(8):956-67. (PMID: 24615900) ; PLoS One. 2016 Apr 13;11(4):e0151190. (PMID: 27073845) ; Proc Natl Acad Sci U S A. 1988 Oct;85(20):7467-70. (PMID: 3174647) ; J Hepatobiliary Pancreat Surg. 2000;7(2):206-11. (PMID: 10982615) ; Parasitol Int. 2012 Mar;61(1):10-6. (PMID: 21893213) ; Sci Rep. 2016 Nov 02;6:36278. (PMID: 27805021) ; J Clin Pathol. 2006 Oct;59(10):1073-8. (PMID: 16679351) ; Carcinogenesis. 2002 Jun;23(6):907-22. (PMID: 12082012) ; Metabolism. 2011 Mar;60(3):404-13. (PMID: 20423748) ; J Nutr. 2007 Jan;137(1 Suppl):259S-266S. (PMID: 17182837) ; J Clin Pathol. 2013 Mar;66(3):212-7. (PMID: 23268317) ; J Clin Epidemiol. 2010 Sep;63(9):970-9. (PMID: 20056386) ; Cell Metab. 2009 Apr;9(4):311-26. (PMID: 19356713) ; Ann Nutr Metab. 2014;64(3-4):314-24. (PMID: 25300275) ; Hepat Med. 2019 May 03;11:47-67. (PMID: 31118840) ; Hepatology. 2006 Oct;44(4):1025-38. (PMID: 17006947) ; Metabolomics. 2015;11:9-26. (PMID: 25598764) ; Metabolites. 2021 Jan 14;11(1):. (PMID: 33466750) ; Am J Clin Nutr. 2010 Aug;92(2):436-43. (PMID: 20573794) Grant Information: United Kingdom WT_ Wellcome Trust; 26813 United Kingdom CRUK_ Cancer Research UK Substance Nomenclature: 0 (Biomarkers) Entry Date(s): Date Created: 20211029 Date Completed: 20220127 Latest Revision: 20220424 Update Code: 20240513 PubMed Central ID: PMC8553759

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Mapping of population disparities in the cholangiocarcinoma urinary metabolome.